Douglas R Jeffery, M.D., Ph.D.
Associate Professor
Director of Multiple Sclerosis Center
Research Interests: Neuroimmunology in progressive and relapsing-remitting multiple sclerosis, evaluation of new therapeutic agents for multiple sclerosis and MRI Spectroscopy and diffusion tensor imaging in multiple sclerosis
EDUCATION:
1973-1978 University of Maryland
College Park, Maryland
B.S. (Major-Psychology/Zoology)
1983 State University of New York School of Medicine
Buffalo, New York
Ph.D., Pharmacology and Therapeutics
1987 State University New York School of Medicine
Buffalo, New York
M.D.
POSTDOCTORAL TRAINING:
7/87 - 7/88 Internship Graduate Medical Dental Education Consortium
State University of New York at Buffalo
7/88 - 11/89 Neurology Resident
University of Rochester
Strong Memorial Hospital
7/90 - 6/92 Neurology Resident
Department of Neurology
University of New Mexico
PROFESSIONAL LICENSURE:
New Mexico Current advanced cardiac life support
Expires: October, 1995
North Carolina License
SPECIALTY CERTIFICATION:
March 1994 Certified in Neurorehabilitation through The American Society of Neurorehabilitation
June 1994 Board certified in Neurology
Douglas Jeffery, M.D., Ph.D., completed his undergraduate studies at the University of Maryland, College Park, Maryland. He earned his Ph.D. in Pharmacology and Therapeutics from the State University of New York School of Medicine in Buffalo, New York in 1983. He earned his medical degree from this same institution in 1987. Dr. Jeffery completed his internship program at the State University of New York in Buffalo. He completed his residency in Neurology at the University of New Mexico.
Dr. Jeffery served as a staff physician and instructor for the Department of Neurology and Spinal Cord Injury Unit at the Veterans Administration Medical Center and the University of New Mexico from 7/92 - 12/93. He has been an Assistant Professor in Neurology at the Wake Forest University School of Medicine since January 1994. He was certified on Neurorehabilitation through the American Society of Neurorehabilitation in March of 1994 and board certified in Neurology in June 1994.
Dr. Jeffery's area of clinical and research interest is Multiple Sclerosis. His current grant support includes Teva Marion's "Evaluation of Injected Glatiramer Acetate in Primary Progressive Multiple Sclerosis," Teva Marion's "Evaluation of Oral Glatiramer Acetate in Relapsing Remitting Multiple Sclerosis," Pfizer's "Evaluation of Donepezil in the Treatment of Cognitive Dysfunction in Multiple Sclerosis," Immunex's and Berlex's "Evaluation of Mitoxantrone in Treatment of Multiple Sclerosis," and Elan's "Evaluation of Zanaflex Modified Release in the Treatment Spasticity in Multiple Sclerosis and Spinal Cord Injury."
Publications:
Jeffery DR, Absher J, Pfeiffer FE, Jackson H. Cortical Deficits in Multiple Sclerosis on the Basis of Subcortical Lesions. Multiple Sclerosis, 2000;6:50-55.
Noseworthy JH, Wolinsky JR, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, Sullivan HC, North American Linomide Investigators (Jeffery DR, et al.) Linomide in Relapsing and Secondary Progressive MS: Part I:Trial Design and Clinical Results. Neurology, May 2000;54:1726-1733.
Wolinsky JS, Narayana PA, Noseworthy JH, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, Sullivan HC, MRI Analysis Center, North American Linomide Investigators (Jeffery DR, et al.) Linomide in Relapsing and Secondary Progressive MS: Part II: MRI Results. Neurology, May 2000;54:1734-1741.
Jeffery DR. Relationship Between Disease Activity and Dose-Response Relationships with Beta Interferon Therapies in the Treatment of Multiple Sclerosis. Journal of Neurologic Sciences, 2000;178:2-9
North American Interferon β-1b Study Group (Jeffery, DR, et al.). North American Trial for Betaseron in Secondary Progressive MS. 2000.
Jeffery DR. Optimizing Immunomodulatory Therapy For MS Patients: An Integrated Management Model. Journal of Neurologic Sciences, 2002;89-90.
Jeffery DR. The Use of Vaccinations in Patients With Multiple Sclerosis. Infections in Medicine 2002;73-79.
Jeffery DR. Interferon Beta: Maximizing The Benefits. Multiple Sclerosis Quarterly Report, Spring of 2002;11-13.
Jeffery DR. Use of Adrenocorticosteroid Hormones in the Treatment of Multiple Sclerosis. Expert Rec. Neurotherapeutics 2002;2(6):859-866.
Jeffery DR. Early Intervention With Immunomodulatory Agents in the Treatment of Multiple Sclerosis. Journal of Neurological Sciences. February 2002;197:1-8
MS Patient Management: Optimizing the Benefits of Immunomodulatory Therapy. International Journal of MS Care. May 2002; 3-7.
Jeffery DR, Lefkowitz DS, and Crittenden JP. Treatment of Marburg Variant Multiple Sclerosis with Mitoxantrone. Journal of Neuroimaging. Jan 2004;14(1):58-62.
Jeffery DR. The Argument Against the Use of Cyclophosphamide and Mitoxantrone in the Treatment of Multiple Sclerosis. J Neurol. Sci. August 2004;223(1):41-46.
Jeffery DR and Herndon R. Review of Mitoxantrone in the Treatment of Multiple Sclerosis. Neurology. 2004 Dec 28;63(12 Supl 6):S19-24.
Jeffery DR. Use of Combination Therapy with Immunomodulators and Immunosuppressants in Treating Multiple Sclerosis. Neurology. 2004 Dec 28;63(12 Suppl 6):S41-46.
Cohen BA, Khan O, Jeffery DR, et al. Identifying and Treating Patients with Suboptimal Responses. Neurology. 2004 Dec 28;63(12 Suppl 6):S33-40.
Cohen BA and Jeffery DR. Identification of Suboptimal Responders to Immune Modulating Agents and the Role of Mitoxantrone in Worsening Multiple Sclerosis. Neurology 2004 Dec 28;63(12 Suppl 6):S1-2.
Cartwright MS, Jeffery DR, Nuss GR, Donofrio PD. Statin-associated exacerbation of myasthenia gravis. Neurology. 2004 Dec 14;63(11):2188.
Jeffery DR, Chepuri N, Durden D, Burdette J. A Pilot Trial of Combination Therapy with Mitoxantrone and Interferon Beta-1b Using Monthly Gadolinium-Enhanced Magnetic Resonance Imaging. Mult Scler. 2005 June;11(3):296-301
Jeffery DR. Optimizing Patient Treatment: BEYOND Current Treatment. Clinical Trends in Neurology. 2005, 1:31-35
Jeffery DR. Natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 Jun 1;354(22): 2387-9.
Cartwright MS, Jeffery DR, Lewis ZT, Koty PP, Stewart WT, Molnar I. Mitoxantrone for Multiple Sclerosis Causing Acute Lymphoblastic Leukemia. Neurology 2007; 68:19; 1630
Banwell B, Jeffery DR, Ness J., Weinstock-Guttman B., Schwid S. and the Pediatric Multiple Sclerosis Working Group. MRI Features of Pediatric Multiple Sclerosis, Neurology, 2007;68:S46-S53
Bigley GK, Coyle P, Jeffery DR. Potential Changes to Current Immunomodulatory Therapies for MS, Update on Ongoing Clinical Trials, MS Update, Vol. 1, Issue 1, April 2007